nodes	percent_of_prediction	percent_of_DWPC	metapath
Fosaprepitant—Hypersensitivity—Ifosfamide—testicular cancer	0.00131	0.00131	CcSEcCtD
Fosaprepitant—Stevens-Johnson syndrome—Methotrexate—testicular cancer	0.00131	0.00131	CcSEcCtD
Fosaprepitant—Alanine aminotransferase increased—Doxorubicin—testicular cancer	0.00131	0.00131	CcSEcCtD
Fosaprepitant—Muscular weakness—Doxorubicin—testicular cancer	0.00131	0.00131	CcSEcCtD
Fosaprepitant—Dysuria—Epirubicin—testicular cancer	0.00129	0.00129	CcSEcCtD
Fosaprepitant—Abdominal distension—Doxorubicin—testicular cancer	0.00129	0.00129	CcSEcCtD
Fosaprepitant—Stomatitis—Methotrexate—testicular cancer	0.00129	0.00129	CcSEcCtD
Fosaprepitant—Conjunctivitis—Methotrexate—testicular cancer	0.00128	0.00128	CcSEcCtD
Fosaprepitant—Pollakiuria—Epirubicin—testicular cancer	0.00128	0.00128	CcSEcCtD
Fosaprepitant—Asthenia—Ifosfamide—testicular cancer	0.00128	0.00128	CcSEcCtD
Fosaprepitant—Photosensitivity reaction—Epirubicin—testicular cancer	0.00126	0.00126	CcSEcCtD
Fosaprepitant—Feeling abnormal—Cisplatin—testicular cancer	0.00126	0.00126	CcSEcCtD
Fosaprepitant—Pruritus—Ifosfamide—testicular cancer	0.00126	0.00126	CcSEcCtD
Fosaprepitant—Haematuria—Methotrexate—testicular cancer	0.00126	0.00126	CcSEcCtD
Fosaprepitant—Weight decreased—Epirubicin—testicular cancer	0.00125	0.00125	CcSEcCtD
Fosaprepitant—Dyspnoea—Etoposide—testicular cancer	0.00125	0.00125	CcSEcCtD
Fosaprepitant—Somnolence—Etoposide—testicular cancer	0.00125	0.00125	CcSEcCtD
Fosaprepitant—Nausea—Bleomycin—testicular cancer	0.00124	0.00124	CcSEcCtD
Fosaprepitant—Infestation NOS—Epirubicin—testicular cancer	0.00123	0.00123	CcSEcCtD
Fosaprepitant—Infestation—Epirubicin—testicular cancer	0.00123	0.00123	CcSEcCtD
Fosaprepitant—Vomiting—Dactinomycin—testicular cancer	0.00123	0.00123	CcSEcCtD
Fosaprepitant—Stevens-Johnson syndrome—Epirubicin—testicular cancer	0.00122	0.00122	CcSEcCtD
Fosaprepitant—Rash—Dactinomycin—testicular cancer	0.00122	0.00122	CcSEcCtD
Fosaprepitant—Decreased appetite—Etoposide—testicular cancer	0.00122	0.00122	CcSEcCtD
Fosaprepitant—Diarrhoea—Ifosfamide—testicular cancer	0.00122	0.00122	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Etoposide—testicular cancer	0.00121	0.00121	CcSEcCtD
Fosaprepitant—Body temperature increased—Cisplatin—testicular cancer	0.00121	0.00121	CcSEcCtD
Fosaprepitant—Fatigue—Etoposide—testicular cancer	0.00121	0.00121	CcSEcCtD
Fosaprepitant—Stomatitis—Epirubicin—testicular cancer	0.0012	0.0012	CcSEcCtD
Fosaprepitant—Constipation—Etoposide—testicular cancer	0.0012	0.0012	CcSEcCtD
Fosaprepitant—Pain—Etoposide—testicular cancer	0.0012	0.0012	CcSEcCtD
Fosaprepitant—Conjunctivitis—Epirubicin—testicular cancer	0.0012	0.0012	CcSEcCtD
Fosaprepitant—Urinary tract infection—Epirubicin—testicular cancer	0.0012	0.0012	CcSEcCtD
Fosaprepitant—Dysuria—Doxorubicin—testicular cancer	0.0012	0.0012	CcSEcCtD
Fosaprepitant—Pollakiuria—Doxorubicin—testicular cancer	0.00118	0.00118	CcSEcCtD
Fosaprepitant—Haematuria—Epirubicin—testicular cancer	0.00118	0.00118	CcSEcCtD
Fosaprepitant—Dizziness—Ifosfamide—testicular cancer	0.00118	0.00118	CcSEcCtD
Fosaprepitant—Urinary tract disorder—Methotrexate—testicular cancer	0.00117	0.00117	CcSEcCtD
Fosaprepitant—Photosensitivity reaction—Doxorubicin—testicular cancer	0.00117	0.00117	CcSEcCtD
Fosaprepitant—Urethral disorder—Methotrexate—testicular cancer	0.00116	0.00116	CcSEcCtD
Fosaprepitant—Weight decreased—Doxorubicin—testicular cancer	0.00116	0.00116	CcSEcCtD
Fosaprepitant—Feeling abnormal—Etoposide—testicular cancer	0.00116	0.00116	CcSEcCtD
Fosaprepitant—Nausea—Dactinomycin—testicular cancer	0.00115	0.00115	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Etoposide—testicular cancer	0.00115	0.00115	CcSEcCtD
Fosaprepitant—Infestation—Doxorubicin—testicular cancer	0.00114	0.00114	CcSEcCtD
Fosaprepitant—Infestation NOS—Doxorubicin—testicular cancer	0.00114	0.00114	CcSEcCtD
Fosaprepitant—Stevens-Johnson syndrome—Doxorubicin—testicular cancer	0.00113	0.00113	CcSEcCtD
Fosaprepitant—Vomiting—Ifosfamide—testicular cancer	0.00113	0.00113	CcSEcCtD
Fosaprepitant—Hypersensitivity—Cisplatin—testicular cancer	0.00113	0.00113	CcSEcCtD
Fosaprepitant—Bradycardia—Epirubicin—testicular cancer	0.00113	0.00113	CcSEcCtD
Fosaprepitant—Rash—Ifosfamide—testicular cancer	0.00112	0.00112	CcSEcCtD
Fosaprepitant—Dermatitis—Ifosfamide—testicular cancer	0.00112	0.00112	CcSEcCtD
Fosaprepitant—Erythema multiforme—Methotrexate—testicular cancer	0.00112	0.00112	CcSEcCtD
Fosaprepitant—Urticaria—Etoposide—testicular cancer	0.00112	0.00112	CcSEcCtD
Fosaprepitant—Stomatitis—Doxorubicin—testicular cancer	0.00111	0.00111	CcSEcCtD
Fosaprepitant—Abdominal pain—Etoposide—testicular cancer	0.00111	0.00111	CcSEcCtD
Fosaprepitant—Body temperature increased—Etoposide—testicular cancer	0.00111	0.00111	CcSEcCtD
Fosaprepitant—Urinary tract infection—Doxorubicin—testicular cancer	0.00111	0.00111	CcSEcCtD
Fosaprepitant—Conjunctivitis—Doxorubicin—testicular cancer	0.00111	0.00111	CcSEcCtD
Fosaprepitant—Eye disorder—Methotrexate—testicular cancer	0.00111	0.00111	CcSEcCtD
Fosaprepitant—Tinnitus—Methotrexate—testicular cancer	0.0011	0.0011	CcSEcCtD
Fosaprepitant—Hypoaesthesia—Epirubicin—testicular cancer	0.0011	0.0011	CcSEcCtD
Fosaprepitant—Asthenia—Cisplatin—testicular cancer	0.0011	0.0011	CcSEcCtD
Fosaprepitant—Cardiac disorder—Methotrexate—testicular cancer	0.0011	0.0011	CcSEcCtD
Fosaprepitant—Urinary tract disorder—Epirubicin—testicular cancer	0.00109	0.00109	CcSEcCtD
Fosaprepitant—Haematuria—Doxorubicin—testicular cancer	0.00109	0.00109	CcSEcCtD
Fosaprepitant—Connective tissue disorder—Epirubicin—testicular cancer	0.00109	0.00109	CcSEcCtD
Fosaprepitant—Urethral disorder—Epirubicin—testicular cancer	0.00109	0.00109	CcSEcCtD
Fosaprepitant—Angiopathy—Methotrexate—testicular cancer	0.00107	0.00107	CcSEcCtD
Fosaprepitant—Immune system disorder—Methotrexate—testicular cancer	0.00107	0.00107	CcSEcCtD
Fosaprepitant—Mediastinal disorder—Methotrexate—testicular cancer	0.00107	0.00107	CcSEcCtD
Fosaprepitant—Nausea—Ifosfamide—testicular cancer	0.00106	0.00106	CcSEcCtD
Fosaprepitant—Diarrhoea—Cisplatin—testicular cancer	0.00105	0.00105	CcSEcCtD
Fosaprepitant—Erythema multiforme—Epirubicin—testicular cancer	0.00105	0.00105	CcSEcCtD
Fosaprepitant—Bradycardia—Doxorubicin—testicular cancer	0.00104	0.00104	CcSEcCtD
Fosaprepitant—Mental disorder—Methotrexate—testicular cancer	0.00104	0.00104	CcSEcCtD
Fosaprepitant—Eye disorder—Epirubicin—testicular cancer	0.00104	0.00104	CcSEcCtD
Fosaprepitant—Hypersensitivity—Etoposide—testicular cancer	0.00103	0.00103	CcSEcCtD
Fosaprepitant—Tinnitus—Epirubicin—testicular cancer	0.00103	0.00103	CcSEcCtD
Fosaprepitant—Erythema—Methotrexate—testicular cancer	0.00103	0.00103	CcSEcCtD
Fosaprepitant—Malnutrition—Methotrexate—testicular cancer	0.00103	0.00103	CcSEcCtD
Fosaprepitant—Cardiac disorder—Epirubicin—testicular cancer	0.00103	0.00103	CcSEcCtD
Fosaprepitant—Flushing—Epirubicin—testicular cancer	0.00103	0.00103	CcSEcCtD
Fosaprepitant—Hypoaesthesia—Doxorubicin—testicular cancer	0.00102	0.00102	CcSEcCtD
Fosaprepitant—Urinary tract disorder—Doxorubicin—testicular cancer	0.00101	0.00101	CcSEcCtD
Fosaprepitant—Dysgeusia—Methotrexate—testicular cancer	0.00101	0.00101	CcSEcCtD
Fosaprepitant—Asthenia—Etoposide—testicular cancer	0.00101	0.00101	CcSEcCtD
Fosaprepitant—Connective tissue disorder—Doxorubicin—testicular cancer	0.00101	0.00101	CcSEcCtD
Fosaprepitant—Angiopathy—Epirubicin—testicular cancer	0.00101	0.00101	CcSEcCtD
Fosaprepitant—Urethral disorder—Doxorubicin—testicular cancer	0.001	0.001	CcSEcCtD
Fosaprepitant—Immune system disorder—Epirubicin—testicular cancer	0.001	0.001	CcSEcCtD
Fosaprepitant—Mediastinal disorder—Epirubicin—testicular cancer	0.000998	0.000998	CcSEcCtD
Fosaprepitant—Pruritus—Etoposide—testicular cancer	0.000993	0.000993	CcSEcCtD
Fosaprepitant—Vomiting—Cisplatin—testicular cancer	0.000974	0.000974	CcSEcCtD
Fosaprepitant—Mental disorder—Epirubicin—testicular cancer	0.000971	0.000971	CcSEcCtD
Fosaprepitant—Erythema multiforme—Doxorubicin—testicular cancer	0.000969	0.000969	CcSEcCtD
Fosaprepitant—Rash—Cisplatin—testicular cancer	0.000966	0.000966	CcSEcCtD
Fosaprepitant—Dermatitis—Cisplatin—testicular cancer	0.000965	0.000965	CcSEcCtD
Fosaprepitant—Erythema—Epirubicin—testicular cancer	0.000964	0.000964	CcSEcCtD
Fosaprepitant—Malnutrition—Epirubicin—testicular cancer	0.000964	0.000964	CcSEcCtD
Fosaprepitant—Diarrhoea—Etoposide—testicular cancer	0.000961	0.000961	CcSEcCtD
Fosaprepitant—Eye disorder—Doxorubicin—testicular cancer	0.000958	0.000958	CcSEcCtD
Fosaprepitant—Ill-defined disorder—Methotrexate—testicular cancer	0.000956	0.000956	CcSEcCtD
Fosaprepitant—Tinnitus—Doxorubicin—testicular cancer	0.000956	0.000956	CcSEcCtD
Fosaprepitant—Anaemia—Methotrexate—testicular cancer	0.000952	0.000952	CcSEcCtD
Fosaprepitant—Cardiac disorder—Doxorubicin—testicular cancer	0.000951	0.000951	CcSEcCtD
Fosaprepitant—Flushing—Doxorubicin—testicular cancer	0.000951	0.000951	CcSEcCtD
Fosaprepitant—Flatulence—Epirubicin—testicular cancer	0.00095	0.00095	CcSEcCtD
Fosaprepitant—Dysgeusia—Epirubicin—testicular cancer	0.000944	0.000944	CcSEcCtD
Fosaprepitant—Angiopathy—Doxorubicin—testicular cancer	0.00093	0.00093	CcSEcCtD
Fosaprepitant—Malaise—Methotrexate—testicular cancer	0.000929	0.000929	CcSEcCtD
Fosaprepitant—Dizziness—Etoposide—testicular cancer	0.000929	0.000929	CcSEcCtD
Fosaprepitant—Muscle spasms—Epirubicin—testicular cancer	0.000927	0.000927	CcSEcCtD
Fosaprepitant—Immune system disorder—Doxorubicin—testicular cancer	0.000926	0.000926	CcSEcCtD
Fosaprepitant—Mediastinal disorder—Doxorubicin—testicular cancer	0.000924	0.000924	CcSEcCtD
Fosaprepitant—Nausea—Cisplatin—testicular cancer	0.00091	0.00091	CcSEcCtD
Fosaprepitant—Cough—Methotrexate—testicular cancer	0.000899	0.000899	CcSEcCtD
Fosaprepitant—Mental disorder—Doxorubicin—testicular cancer	0.000898	0.000898	CcSEcCtD
Fosaprepitant—Ill-defined disorder—Epirubicin—testicular cancer	0.000895	0.000895	CcSEcCtD
Fosaprepitant—Vomiting—Etoposide—testicular cancer	0.000893	0.000893	CcSEcCtD
Fosaprepitant—Malnutrition—Doxorubicin—testicular cancer	0.000892	0.000892	CcSEcCtD
Fosaprepitant—Erythema—Doxorubicin—testicular cancer	0.000892	0.000892	CcSEcCtD
Fosaprepitant—Anaemia—Epirubicin—testicular cancer	0.000891	0.000891	CcSEcCtD
Fosaprepitant—Rash—Etoposide—testicular cancer	0.000885	0.000885	CcSEcCtD
Fosaprepitant—Dermatitis—Etoposide—testicular cancer	0.000885	0.000885	CcSEcCtD
Fosaprepitant—Headache—Etoposide—testicular cancer	0.00088	0.00088	CcSEcCtD
Fosaprepitant—Flatulence—Doxorubicin—testicular cancer	0.000879	0.000879	CcSEcCtD
Fosaprepitant—Chest pain—Methotrexate—testicular cancer	0.000877	0.000877	CcSEcCtD
Fosaprepitant—Dysgeusia—Doxorubicin—testicular cancer	0.000874	0.000874	CcSEcCtD
Fosaprepitant—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000871	0.000871	CcSEcCtD
Fosaprepitant—Malaise—Epirubicin—testicular cancer	0.00087	0.00087	CcSEcCtD
Fosaprepitant—Discomfort—Methotrexate—testicular cancer	0.000867	0.000867	CcSEcCtD
Fosaprepitant—Syncope—Epirubicin—testicular cancer	0.000865	0.000865	CcSEcCtD
Fosaprepitant—Muscle spasms—Doxorubicin—testicular cancer	0.000858	0.000858	CcSEcCtD
Fosaprepitant—Palpitations—Epirubicin—testicular cancer	0.000852	0.000852	CcSEcCtD
Fosaprepitant—Loss of consciousness—Epirubicin—testicular cancer	0.000848	0.000848	CcSEcCtD
Fosaprepitant—Cough—Epirubicin—testicular cancer	0.000842	0.000842	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Methotrexate—testicular cancer	0.000841	0.000841	CcSEcCtD
Fosaprepitant—Infection—Methotrexate—testicular cancer	0.000836	0.000836	CcSEcCtD
Fosaprepitant—Nausea—Etoposide—testicular cancer	0.000834	0.000834	CcSEcCtD
Fosaprepitant—Hypertension—Epirubicin—testicular cancer	0.000833	0.000833	CcSEcCtD
Fosaprepitant—Ill-defined disorder—Doxorubicin—testicular cancer	0.000828	0.000828	CcSEcCtD
Fosaprepitant—Nervous system disorder—Methotrexate—testicular cancer	0.000825	0.000825	CcSEcCtD
Fosaprepitant—Anaemia—Doxorubicin—testicular cancer	0.000825	0.000825	CcSEcCtD
Fosaprepitant—Chest pain—Epirubicin—testicular cancer	0.000821	0.000821	CcSEcCtD
Fosaprepitant—Anxiety—Epirubicin—testicular cancer	0.000818	0.000818	CcSEcCtD
Fosaprepitant—Skin disorder—Methotrexate—testicular cancer	0.000817	0.000817	CcSEcCtD
Fosaprepitant—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000815	0.000815	CcSEcCtD
Fosaprepitant—Hyperhidrosis—Methotrexate—testicular cancer	0.000813	0.000813	CcSEcCtD
Fosaprepitant—Discomfort—Epirubicin—testicular cancer	0.000811	0.000811	CcSEcCtD
Fosaprepitant—Malaise—Doxorubicin—testicular cancer	0.000805	0.000805	CcSEcCtD
Fosaprepitant—Dry mouth—Epirubicin—testicular cancer	0.000803	0.000803	CcSEcCtD
Fosaprepitant—Syncope—Doxorubicin—testicular cancer	0.0008	0.0008	CcSEcCtD
Fosaprepitant—Palpitations—Doxorubicin—testicular cancer	0.000789	0.000789	CcSEcCtD
Fosaprepitant—Oedema—Epirubicin—testicular cancer	0.000787	0.000787	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Epirubicin—testicular cancer	0.000787	0.000787	CcSEcCtD
Fosaprepitant—Hypotension—Methotrexate—testicular cancer	0.000786	0.000786	CcSEcCtD
Fosaprepitant—Loss of consciousness—Doxorubicin—testicular cancer	0.000784	0.000784	CcSEcCtD
Fosaprepitant—Infection—Epirubicin—testicular cancer	0.000782	0.000782	CcSEcCtD
Fosaprepitant—Cough—Doxorubicin—testicular cancer	0.000779	0.000779	CcSEcCtD
Fosaprepitant—Shock—Epirubicin—testicular cancer	0.000774	0.000774	CcSEcCtD
Fosaprepitant—Nervous system disorder—Epirubicin—testicular cancer	0.000772	0.000772	CcSEcCtD
Fosaprepitant—Hypertension—Doxorubicin—testicular cancer	0.00077	0.00077	CcSEcCtD
Fosaprepitant—Skin disorder—Epirubicin—testicular cancer	0.000765	0.000765	CcSEcCtD
Fosaprepitant—Hyperhidrosis—Epirubicin—testicular cancer	0.000761	0.000761	CcSEcCtD
Fosaprepitant—Insomnia—Methotrexate—testicular cancer	0.000761	0.000761	CcSEcCtD
Fosaprepitant—Chest pain—Doxorubicin—testicular cancer	0.00076	0.00076	CcSEcCtD
Fosaprepitant—Anxiety—Doxorubicin—testicular cancer	0.000757	0.000757	CcSEcCtD
Fosaprepitant—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.000754	0.000754	CcSEcCtD
Fosaprepitant—Discomfort—Doxorubicin—testicular cancer	0.000751	0.000751	CcSEcCtD
Fosaprepitant—Dyspnoea—Methotrexate—testicular cancer	0.00075	0.00075	CcSEcCtD
Fosaprepitant—Somnolence—Methotrexate—testicular cancer	0.000748	0.000748	CcSEcCtD
Fosaprepitant—Dry mouth—Doxorubicin—testicular cancer	0.000743	0.000743	CcSEcCtD
Fosaprepitant—Dyspepsia—Methotrexate—testicular cancer	0.00074	0.00074	CcSEcCtD
Fosaprepitant—Hypotension—Epirubicin—testicular cancer	0.000735	0.000735	CcSEcCtD
Fosaprepitant—Decreased appetite—Methotrexate—testicular cancer	0.000731	0.000731	CcSEcCtD
Fosaprepitant—Oedema—Doxorubicin—testicular cancer	0.000728	0.000728	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Doxorubicin—testicular cancer	0.000728	0.000728	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000726	0.000726	CcSEcCtD
Fosaprepitant—Fatigue—Methotrexate—testicular cancer	0.000725	0.000725	CcSEcCtD
Fosaprepitant—Infection—Doxorubicin—testicular cancer	0.000724	0.000724	CcSEcCtD
Fosaprepitant—Pain—Methotrexate—testicular cancer	0.000719	0.000719	CcSEcCtD
Fosaprepitant—Shock—Doxorubicin—testicular cancer	0.000716	0.000716	CcSEcCtD
Fosaprepitant—Nervous system disorder—Doxorubicin—testicular cancer	0.000714	0.000714	CcSEcCtD
Fosaprepitant—Insomnia—Epirubicin—testicular cancer	0.000712	0.000712	CcSEcCtD
Fosaprepitant—Skin disorder—Doxorubicin—testicular cancer	0.000707	0.000707	CcSEcCtD
Fosaprepitant—Hyperhidrosis—Doxorubicin—testicular cancer	0.000704	0.000704	CcSEcCtD
Fosaprepitant—Dyspnoea—Epirubicin—testicular cancer	0.000702	0.000702	CcSEcCtD
Fosaprepitant—Somnolence—Epirubicin—testicular cancer	0.0007	0.0007	CcSEcCtD
Fosaprepitant—Feeling abnormal—Methotrexate—testicular cancer	0.000693	0.000693	CcSEcCtD
Fosaprepitant—Dyspepsia—Epirubicin—testicular cancer	0.000693	0.000693	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Methotrexate—testicular cancer	0.000688	0.000688	CcSEcCtD
Fosaprepitant—Decreased appetite—Epirubicin—testicular cancer	0.000684	0.000684	CcSEcCtD
Fosaprepitant—Hypotension—Doxorubicin—testicular cancer	0.000681	0.000681	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Epirubicin—testicular cancer	0.00068	0.00068	CcSEcCtD
Fosaprepitant—Fatigue—Epirubicin—testicular cancer	0.000679	0.000679	CcSEcCtD
Fosaprepitant—Pain—Epirubicin—testicular cancer	0.000673	0.000673	CcSEcCtD
Fosaprepitant—Constipation—Epirubicin—testicular cancer	0.000673	0.000673	CcSEcCtD
Fosaprepitant—Urticaria—Methotrexate—testicular cancer	0.000668	0.000668	CcSEcCtD
Fosaprepitant—Body temperature increased—Methotrexate—testicular cancer	0.000665	0.000665	CcSEcCtD
Fosaprepitant—Abdominal pain—Methotrexate—testicular cancer	0.000665	0.000665	CcSEcCtD
Fosaprepitant—Insomnia—Doxorubicin—testicular cancer	0.000659	0.000659	CcSEcCtD
Fosaprepitant—Dyspnoea—Doxorubicin—testicular cancer	0.000649	0.000649	CcSEcCtD
Fosaprepitant—Feeling abnormal—Epirubicin—testicular cancer	0.000649	0.000649	CcSEcCtD
Fosaprepitant—Somnolence—Doxorubicin—testicular cancer	0.000647	0.000647	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Epirubicin—testicular cancer	0.000644	0.000644	CcSEcCtD
Fosaprepitant—Dyspepsia—Doxorubicin—testicular cancer	0.000641	0.000641	CcSEcCtD
Fosaprepitant—Decreased appetite—Doxorubicin—testicular cancer	0.000633	0.000633	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000629	0.000629	CcSEcCtD
Fosaprepitant—Fatigue—Doxorubicin—testicular cancer	0.000628	0.000628	CcSEcCtD
Fosaprepitant—Urticaria—Epirubicin—testicular cancer	0.000625	0.000625	CcSEcCtD
Fosaprepitant—Pain—Doxorubicin—testicular cancer	0.000623	0.000623	CcSEcCtD
Fosaprepitant—Constipation—Doxorubicin—testicular cancer	0.000623	0.000623	CcSEcCtD
Fosaprepitant—Abdominal pain—Epirubicin—testicular cancer	0.000622	0.000622	CcSEcCtD
Fosaprepitant—Body temperature increased—Epirubicin—testicular cancer	0.000622	0.000622	CcSEcCtD
Fosaprepitant—Hypersensitivity—Methotrexate—testicular cancer	0.00062	0.00062	CcSEcCtD
Fosaprepitant—Asthenia—Methotrexate—testicular cancer	0.000603	0.000603	CcSEcCtD
Fosaprepitant—Feeling abnormal—Doxorubicin—testicular cancer	0.0006	0.0006	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Doxorubicin—testicular cancer	0.000596	0.000596	CcSEcCtD
Fosaprepitant—Pruritus—Methotrexate—testicular cancer	0.000595	0.000595	CcSEcCtD
Fosaprepitant—Hypersensitivity—Epirubicin—testicular cancer	0.00058	0.00058	CcSEcCtD
Fosaprepitant—Urticaria—Doxorubicin—testicular cancer	0.000579	0.000579	CcSEcCtD
Fosaprepitant—Abdominal pain—Doxorubicin—testicular cancer	0.000576	0.000576	CcSEcCtD
Fosaprepitant—Body temperature increased—Doxorubicin—testicular cancer	0.000576	0.000576	CcSEcCtD
Fosaprepitant—Diarrhoea—Methotrexate—testicular cancer	0.000575	0.000575	CcSEcCtD
Fosaprepitant—Asthenia—Epirubicin—testicular cancer	0.000565	0.000565	CcSEcCtD
Fosaprepitant—Pruritus—Epirubicin—testicular cancer	0.000557	0.000557	CcSEcCtD
Fosaprepitant—Dizziness—Methotrexate—testicular cancer	0.000556	0.000556	CcSEcCtD
Fosaprepitant—Diarrhoea—Epirubicin—testicular cancer	0.000539	0.000539	CcSEcCtD
Fosaprepitant—Hypersensitivity—Doxorubicin—testicular cancer	0.000537	0.000537	CcSEcCtD
Fosaprepitant—Vomiting—Methotrexate—testicular cancer	0.000535	0.000535	CcSEcCtD
Fosaprepitant—Rash—Methotrexate—testicular cancer	0.00053	0.00053	CcSEcCtD
Fosaprepitant—Dermatitis—Methotrexate—testicular cancer	0.00053	0.00053	CcSEcCtD
Fosaprepitant—Headache—Methotrexate—testicular cancer	0.000527	0.000527	CcSEcCtD
Fosaprepitant—Asthenia—Doxorubicin—testicular cancer	0.000523	0.000523	CcSEcCtD
Fosaprepitant—Dizziness—Epirubicin—testicular cancer	0.00052	0.00052	CcSEcCtD
Fosaprepitant—Pruritus—Doxorubicin—testicular cancer	0.000515	0.000515	CcSEcCtD
Fosaprepitant—Vomiting—Epirubicin—testicular cancer	0.0005	0.0005	CcSEcCtD
Fosaprepitant—Nausea—Methotrexate—testicular cancer	0.0005	0.0005	CcSEcCtD
Fosaprepitant—Diarrhoea—Doxorubicin—testicular cancer	0.000498	0.000498	CcSEcCtD
Fosaprepitant—Rash—Epirubicin—testicular cancer	0.000496	0.000496	CcSEcCtD
Fosaprepitant—Dermatitis—Epirubicin—testicular cancer	0.000496	0.000496	CcSEcCtD
Fosaprepitant—Headache—Epirubicin—testicular cancer	0.000493	0.000493	CcSEcCtD
Fosaprepitant—Dizziness—Doxorubicin—testicular cancer	0.000482	0.000482	CcSEcCtD
Fosaprepitant—Nausea—Epirubicin—testicular cancer	0.000468	0.000468	CcSEcCtD
Fosaprepitant—Vomiting—Doxorubicin—testicular cancer	0.000463	0.000463	CcSEcCtD
Fosaprepitant—Rash—Doxorubicin—testicular cancer	0.000459	0.000459	CcSEcCtD
Fosaprepitant—Dermatitis—Doxorubicin—testicular cancer	0.000459	0.000459	CcSEcCtD
Fosaprepitant—Headache—Doxorubicin—testicular cancer	0.000456	0.000456	CcSEcCtD
Fosaprepitant—Nausea—Doxorubicin—testicular cancer	0.000433	0.000433	CcSEcCtD
